Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice

摘要

IntroductionPrednisone is frequently administered in combination with other therapies for the treatment of rheumatoid arthritis (RA); however, its chronic use is associated with an increased risk of comorbidities and mortality. The objective of this analysis was to evaluate changes in prednisone use among patients with RA treated with tocilizumab (TCZ) in routine US clinical practice. MethodsTCZ-na?ve patients in the Corrona RA registry who initiated TCZ were included. The primary outcome was the proportion of patients with changes in prednisone use over 12?months (primary analysis) and 6?months (secondary analysis). Changes in disease activity over 6 and 12?months (±?3?months) were assessed using the Clinical Disease Activity Index (CDAI). Outcomes were assessed in the overall population and separately for patients receiving TCZ monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs. ResultsOf patients receiving prednisone at baseline (mean [SD] dose: 7.7 [5.2] mg/day), 30.6% discontinued prednisone over 12?months; among patients receiving??7.5?mg of prednisone at the time of TCZ initiation, 63.0% discontinued prednisone or decreased their dose by?≥?5?mg over 12?months. In secondary analyses, 29.7% of patients receiving prednisone at baseline had discontinued prednisone over 6?months; among those receiving??7.5?mg of prednisone at baseline, 51.3% discontinued or decreased their dose by?≥?5?mg over 6?months. Changes in prednisone use and improvement from baseline in CDAI score over 6 and 12?months were comparable between patients who initiated TCZ monotherapy vs. TCZ combination therapy. ConclusionsIn this real-world analysis, many patients initiating TCZ monotherapy or combination therapy were able to discontinue or decrease their prednisone dose over 12?months. Similar changes in prednisone dose were observed over 6?months. Trial RegistrationClinicalTrials.gov identifier, NCT01402661. FundingCorrona, LLC and Genentech, Inc. Plain Language SummaryPlain language summary available for this article.